PRTA•benzinga•
Prothena Reveals Phase 3 AFFIRM-AL Clinical Trial for Birtamimab In Patients With AL Amyloidosis Did Not Meet Primary Endpoint
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 23, 2025 by benzinga